

Food-specific IgG₄ is associated with eosinophilic esophagitis



To the Editor:

Our understanding of eosinophilic esophagitis (EoE) pathogenesis is incomplete, but repetitive antigen exposure plays a role in most patients. Skin prick testing, serum IgE levels, and atopy patch testing in some centers have been used to guide dietary elimination, but there is insufficient data to suggest that they are superior to empiric elimination of common food triggers.¹ Recent data suggest a possible association between EoE and elevated levels of total IgG₄ (T-IgG₄), and that IgG₄ may be implicated in disease pathogenesis.²

The role of IgG₄ in EoE is unclear. Clayton et al² showed that esophageal IgG₄ deposits in EoE derive from dense plasma cell infiltrates in the lamina propria. Moreover, data from one study noted that intrasquamous deposits of IgG₄ may distinguish patients with gastroesophageal reflux disease versus EoE.³ These observations suggest potential associations between EoE and IgG₄-related diseases. Nonetheless, food-specific IgG₄ (FS-IgG₄) has also been shown to inhibit basophil and mast cell responses⁴; indeed, FS-IgG₄:IgE ratios have been identified as markers of sustained unresponsiveness⁵ and oral tolerance.⁶ We speculate that IgG₄ may be a marker of epithelial disruption produced initially to attenuate IgE-mediated disease but that, ultimately, results in a proinflammatory process in susceptible atopic hosts. Evidence for this concept may be supported by the development of EoE in some subjects undergoing oral immunotherapy.⁷

Because common food allergens are primary triggers of EoE, the aim of this study was to examine the role of FS-IgG₄ in the pathogenesis of EoE. We hypothesized that FS-IgG₄ levels would be elevated in subjects with active EoE compared with controls, decrease with successful dietary elimination, and correlate with known food triggers.

We performed a case control study of 20 adult subjects with EoE and 10 controls without EoE using prospectively banked specimens from the University of North Carolina EoE Registry and Biobank. Details regarding recruitment, specimens, and data collection have been published previously.⁸ Diagnosis of active EoE was defined by consensus guidelines.⁹ Non-EoE controls were subjects with dysphagia or gastroesophageal reflux disease who did not meet histologic criteria for EoE. Subjects with proton pump inhibitor-responsive esophageal eosinophilia were excluded. Subjects diagnosed with EoE were treated with a six food elimination diet where dairy, egg, wheat, soy, peanut/tree nuts, and seafood were eliminated in addition to suspected dietary triggers on the basis of clinical history. Eleven subjects demonstrated histologic resolution of esophageal eosinophilia (<15 eos/hpf) after 6 to 8 weeks of dietary elimination and were classified as diet responders. The 9 remaining subjects were classified as nonresponders. Clinical food triggers were identified by serial reintroduction of individual food groups followed by repeat endoscopy and biopsy at approximately 6-week intervals. Fig E1 in this article's Online Repository at www.jacionline.org illustrates the study design. We measured T-IgG₄ and FS-IgG₄ levels for peanut, soy, egg white, casein, and wheat by ELISA in paired plasma and esophageal homogenates at baseline and following dietary elimination.

Details regarding the study population, methods used for IgG₄ measurement, and statistical analysis are detailed in this article's Online Repository at www.jacionline.org.

Table E1 in this article's Online Repository at www.jacionline.org details the demographic and clinical characteristics of the study population. At baseline, subjects with EoE demonstrated significantly higher levels of T-IgG₄ and FS-IgG₄ in the esophagus in comparison to non-EoE controls (Table I). Similar results were seen in the plasma, although plasma T-IgG₄ did not differ significantly in subjects with EoE. Significant differences were not observed for baseline T-IgG₄ or FS-IgG₄ levels when nonresponders were compared with diet responders. Linear regression analysis of T-IgG₄ and FS-IgG₄ measurements in all subjects revealed positive correlations between esophageal FS-IgG₄ levels and those seen in the plasma (see Fig E2 in this article's Online Repository at www.jacionline.org). Following dietary elimination, esophageal T-IgG₄ declined significantly among responders ($P = .04$) (Fig 1, A), but not among nonresponders. In addition, postelimination T-IgG₄ levels were significantly lower in the responder group than in the nonresponder group ($P = .03$). In diet responders with identified triggers, we observed significant declines in esophageal, but not serum, FS-IgG₄ levels for all trigger foods ($P = .02$) (Fig 1, B). Interestingly, the only subject who demonstrated a slight increase in egg white-specific IgG₄ level was consuming baked egg at the time of follow-up biopsy.

Among the 11 diet responders, baseline esophageal and plasma FS-IgG₄:T-IgG₄ ratios were elevated for most trigger foods (Fig 1, C and D). Some subjects with marked elevations in FS-IgG₄ levels did not have corresponding clinical triggers. Of note, the 1 subject with soy as a trigger was the only subject with elevated esophageal and plasma levels of soy-specific IgG₄. We were not able to derive predictive thresholds of FS-IgG₄ for individual food triggers given the small size of our cohort and large variations in IgG₄ levels among subjects. Interestingly, some subjects with EoE had persistently elevated T-IgG₄ levels despite dietary elimination. Although this may reflect nonadherence, it may also be due to the presence of IgG₄ to food allergens that have not been successfully identified, aeroallergens, or other environmental triggers of EoE.

While interpreting our results, we acknowledge certain limitations. This is a single-center, exploratory study of adult subjects; therefore, the results cannot be generalized to children. The sample size is also relatively small and insufficiently powered to make definitive comparisons between responders and nonresponders or draw conclusions regarding FS-IgG₄ as a marker of specific food triggers. Because most esophageal IgG₄ levels were measured only from a single biopsy specimen, it is possible that more focal deposits of IgG₄ were not detected. Moreover, we did not assess food-specific IgE responses. However, these limitations are balanced by a number of strengths including the study's prospective design, utilization of banked samples collected, stored, and processed in a uniform fashion for all subjects, detailed clinical and dietary elimination information, and blinded analysis of matched tissue and plasma samples.

In summary, we observed in this small sample of adult subjects with EoE that T-IgG₄ and FS-IgG₄ levels are elevated in the esophagus compared with non-EoE controls. We found that when food

TABLE I. Baseline absolute IgG₄ levels in subjects with EoE and controls*

Food-specific IgG ₄ levels	Controls (n = 10)	EoE cases (n = 20)	P value†
Esophageal biopsies, median (IQR)			
Peanut	0.01 (0.01-0.50)	4.05 (0.39-14.5)	.003
Soy	0.01 (0.01-0.01)	2.12 (0.12-4.82)	<.001
Egg white	2.88 (0.01-12.7)	61.4 (21.1-147.3)	<.001
Casein	0.67 (0.01-3.78)	55.8 (5.87-271.5)	<.001
Wheat	1.10 (0.01-3.82)	19.9 (5.13-184.6)	<.001
Total	469 (210-848)	1,847 (551-3,487)	.008
Plasma, median (IQR)			
Peanut	609.0 (153-1731)	2,324 (703.9-18,709)	.04
Soy	54.8 (0.01-1204)	1,141 (436.9-3,549)	.02
Egg white	16,400 (1,683-78,833)	84,147 (30,720-151,476)	.01
Casein	2928 (384-7232)	22,316 (5,113-123,456)	.01
Wheat	4,984 (298-10,388)	14,773 (4,486-119,263)	.04
Total	276,839 (101,755-725,261)	441,092 (146,954-747,240)	.65

IQR, Interquartile range.

*Total and antigen-specific IgG₄ measurements are reported in ng/mL.

†Comparisons of medians by Wilcoxon rank-sum test.




FIG 1. Esophageal IgG₄ level is elevated in subjects with EoE and decreases in response to dietary elimination. **A**, Esophageal T-IgG₄ levels decrease after dietary elimination in diet responders but not in nonresponders. **B**, Esophageal FS-IgG₄ levels to known triggers decrease significantly following dietary elimination. Baseline esophageal (**C**) and plasma (**D**) FS-IgG₄/T-IgG₄ ratios for diet responders with identified triggers. +Denotes a subject who continued to consume baked egg (B). *Denotes confirmed food triggers (C and D).

triggers are eliminated, esophageal T-IgG₄ and FS-IgG₄ levels decrease in diet responders although these trends are not clearly seen in plasma. The presence of FS-IgG₄ in the esophagus of subjects with EoE suggests that chronic antigen exposure in an atopic individual appears to be associated with an antigen-specific IgG₄ response that may contribute to the pathogenesis of EoE.

Benjamin L. Wright, MD^{a,b}
Mike Kulis, PhD^d
Rishu Guo, MD, PhD^d
Kelly A. Orgel, BS^d
W. Asher Wolf, MD^d

A. Wesley Burks, MD^a
Brian P. Vickery, MD^a
Evan S. Dellon, MD^a

From ^athe University of North Carolina School of Medicine, Chapel Hill, NC, and ^bDuke University Medical Center, Durham, NC. E-mail: wright.benjamin@mayo.edu.

This study was funded by the National Institutes of Health (grant nos. T32 AI007062 to B.L.W., K23 DK090073 to E.S.D., and T32 DK007634 to W.A.W.). This project was also supported in part by a Translational Team Science Award with funding provided by the UNC School of Medicine and the National Center for Advancing Translational Sciences, National Institutes of Health, through grant award number UL1TR001111.

Disclosure of potential conflict of interest: B. L. Wright receives research support from the National Institutes of Health (NIH). M. Kulis and W. A. Wolf receive research

support from the NIH. A. W. Burks receives research support from the NIH; serves on the board of the American Academy of Allergy, Asthma & Immunology, Food Allergy Research and Education (FARE), National Institutes of Health Allergy, Immunology, and Transplantation Research Committee, National Institutes of Health Hypersensitivity, Autoimmune, and Immune-mediated Diseases Study Section, Stallergenes, and World Allergy Organization; serves as a consultant for ActoGeniX, Adept Field Solutions, Dow AgroSciences, ExploraMed Development, LLC, Genentech, GLG Research, Inc, Insys Therapeutics, Merck, Regeneron Pharmaceuticals, Inc, Sanofi-Aventis US Inv, SRA International, Valeant Pharmaceuticals North America, LLC, and Epiva Biosciences, Inc; provides testimony for Friday I Eldrege & Clark; receives royalties from the American Society for Microbiology; and has stock in Allertein and Mastcell Pharmaceuticals, Inc. B. P. Vickery receives research support from the NIH and has stock in Aimmune Therapeutics. E. S. Dellon receives research support from the NIH. The rest of the authors declare that they have no relevant conflicts of interest.

REFERENCES

- Henderson CJ, Abonia JP, King EC, Putnam PE, Collins MH, Franciosi JP, et al. Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. *J Allergy Clin Immunol* 2012;129:1570-8.
- Clayton F, Fang JC, Gleich GJ, Lucendo AJ, Olalla JM, Vinson LA, et al. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE. *Gastroenterology* 2014;147:602-9.
- Zukerberg L, Mahadevan K, Selig M, Deshpande V. Esophageal intrasquamous IgG4 deposits: an adjunctive marker to distinguish eosinophilic esophagitis from reflux esophagitis. *Histopathology* October 14, 2015 <http://dx.doi.org/10.1111/his.12892> [Epub ahead of print].
- Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. *J Allergy Clin Immunol* 2014;133:621-31.
- Vickery BP, Scurlock AM, Kulis M, Steele PH, Kamilaris J, Berglund JP, et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. *J Allergy Clin Immunol* 2014;133:468-75.
- Du Toit G, Roberts G, Sayre PH, Bahnson HT, Radulovic S, Santos AF, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. *N Engl J Med* 2015;372:803-13.
- Lucendo AJ, Arias A, Tenias JM. Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis. *Ann Allergy Asthma Immunol* 2014;113:624-9.
- Dellon ES, Rusin S, Gebhart JH, Covey S, Higgins LL, Beitia R, et al. Utility of a noninvasive serum biomarker panel for diagnosis and monitoring of eosinophilic esophagitis: a prospective study. *Am J Gastroenterol* 2015;110:821-7.
- Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. *J Allergy Clin Immunol* 2011;128:3-20.e6; quiz 1-2.

Available online April 6, 2016.
<http://dx.doi.org/10.1016/j.jaci.2016.02.024>

Regulatory B cells and T follicular helper cells are reduced in allergic rhinitis



To the Editor:

Although the role of human regulatory B (Breg) cells in autoimmunity has been extensively studied, there are limited studies exploring the potential importance of Breg cells in allergy.¹⁻⁷ A subset of peripheral blood Breg cells that produces IL-10 (ie, CD19⁺CD73⁻CD25⁺CD71⁺ Breg cells) has recently been demonstrated to inhibit T_H2 responses.¹⁻³ Breg cells express the cell surface markers CD19 (a B-cell marker), CD25 (the alpha chain of the IL-2 receptor also expressed by regulatory T [Treg] cells), and CD71 (a known activation marker of B cells), but express low amounts of CD73 (an ectonucleotidase thought to play a role in T-cell suppression).^{1,2} Murine *in vivo* studies have demonstrated that antigen specificity is required to develop Breg cells capable of secreting IL-10.⁸ Human Breg cells also exhibit

allergen specificity as demonstrated in studies of bee venom-allergic subjects in whom lower circulating phospholipase A₂-specific Breg cells were found in venom-allergic patients compared with venom-tolerant beekeepers and venom immunotherapy patients.¹ Importantly, T follicular helper (T_{FH}) cell production of IL-21 is critical for the maturation of Breg cells and their production of IL-10.⁸

In this study, we investigated whether subjects with allergic rhinitis had reduced numbers of Breg cells, as well as reduced numbers of Breg cells expressing CD25^{hi}, as previous studies of Treg cells have identified the CD25^{hi} population as the Treg-cell subset most effective in inhibiting T-cell responses.⁹ In addition to examining levels of Breg cells and T_{FH} cells in peripheral blood, we ascertained whether Breg cells and T_{FH} cells could be detected in human lymph nodes, a potential site of interaction between Breg cells, T_{FH} cells, and T_H2 cells not previously studied in humans.

To compare circulating levels of Breg cells and T_{FH} cells, PBMCs were isolated from 10 individuals with allergic rhinitis (mean age, 33.8 years; sex, 3 males and 7 females) and 7 nonallergic individuals (mean age, 37.9 years; sex, 2 males and 5 females) in a protocol approved by the University of California San Diego Human Subjects Protection Committee. Allergy status was confirmed by ImmunoCAP specific IgE levels or skin prick testing to cat, dog, cockroach, dust mite, grasses, trees, weeds, and molds (see Table E1 in this article's Online Repository at www.jacionline.org). Using a previously described gating strategy,¹ Breg cells (CD19⁺CD73⁻CD25⁺CD71⁺) were identified in isolated PBMCs by fluorescence-activated cell sorting (FACS) using fluorescently labeled CD19, CD73, CD25, and CD71 antibodies as well as their corresponding isotype controls (eBioscience, San Diego, Calif) (Fig 1, A). We also examined the percentage of Breg cells expressing CD25^{hi}, as previous studies of Treg cells have identified the CD25^{hi} population as the Treg-cell subset most effective in inhibiting T-cell responses (Fig 1, B).⁹ T_{FH}-like cells (previously defined in peripheral blood as CD4⁺PD-1⁺CXCR5⁺ T cells)^{E1,E2} were also detected in PBMCs by FACS using fluorescently labeled CD4, CXCR5, PD-1 antibodies, and their corresponding isotype controls (eBioscience) (Fig 1, A). Human lung lymph nodes were obtained from human lungs postmortem as previously described at the Arkansas Children's Hospital Research Institute in an institutional review board-exempted protocol.^{E3} A single-cell suspension was prepared by mechanical disruption of lymph nodes for FACS analysis to identify Breg cells and T_{FH} cells (as described above for PBMCs). Flow cytometry was performed using the BD Accuri C6 (BD Biosciences, San Jose, Calif) and Novocyte Flow Cytometer (ACEA Biosciences, Inc, San Diego, Calif) and was analyzed using FlowJo software (version 10.0.7; Tree Star, Inc, Ashland, Ore). Statistical analyses were performed using 1-tailed *t* tests and results reported as mean ± SEM.

We found that percentages of CD25⁺ Breg cells (2.45 ± 0.41 vs 5.05 ± 1.42; *P* < .05) and CD25^{hi} Breg cells (0.25 ± 0.05 vs 0.49 ± 0.06; *P* < .01) were lower in individuals with allergic rhinitis than in nonallergic controls (Fig 2, A). The lower levels of Breg cells in subjects with allergic rhinitis tended to cluster in a similar range, while nonallergic individuals exhibited a wider distribution. Our studies are consistent with reports showing that Breg cells are reduced in allergic individuals compared with controls.^{1,2,4,5,7}




FIG E1. Prospectively collected and banked esophageal and plasma specimens were obtained at baseline from subjects with EoE (n = 20) and non-EoE controls (n = 10). After 6 to 8 weeks of dietary elimination, responder status was determined by follow-up endoscopy. Dietary triggers were elucidated in diet responders (n = 11) by serial reintroduction of foods and repeat esophageal biopsy.




FIG E2. Esophageal FS-IgG₄ correlates with plasma FS-IgG₄. Linear regression plots of absolute T-IgG₄ and FS-IgG₄ (peanut, soy, egg white, casein, and wheat) from plasma (y-axis) and esophageal homogenates (x-axis). R^2 values reported for each food antigen.

TABLE E1. Baseline characteristics of the study population

Characteristic	Controls (n = 10)	EoE cases (n = 20)
Age (y), mean \pm SD	43.6 \pm 13.2	35.0 \pm 8.4
Sex: male, n (%)	2 (20)	8 (40)
White, n (%)	7 (70)	18 (90)
Atopic conditions, n (%)		
Asthma	4 (40)	5 (25)
Eczema	0 (0)	1 (5)
Seasonal allergies	5 (50)	16 (80)
Food allergies	1 (10)	10 (50)
Diagnoses		
EoE	—	20 (100)
GERD	8 (80)	—
Esophageal dysmotility	1 (10)	—
Functional	1 (10)	—
Peak eosinophil counts, mean eos/hpf \pm SD		
Baseline	0.2 \pm 0.4	69.2 \pm 65.6
Postdietary elimination (overall)	—	42.9 \pm 56.5
Postelimination (responders; n = 11)	—	4.5 \pm 3.8
Postelimination (nonresponders; n = 10)	—	89.8 \pm 55.5

GERD, Gastroesophageal reflux disease.